Rapid and broad diagnostic methods are needed for the identification of viral agents of gastroenteritis. In this study, we used Luminex xMAP technology to develop a multiplexed assay for the simultaneous identification of major enteric viral pathogens, including rotavirus A (RVA), noroviruses (NoVs) (including genogroups GI and GII), sapoviruses (SaV), human astrovirus (HAstV), enteric adenoviruses (EAds), and human bocavirus 2 (HBoV2). The analytical sensitivity allowed detection of 10 3 (EAds, HBoV2, and RVA) and 10 4 (NoV GI and GII, SaV, and HAstV) copies per reaction mixture. Compared to conventional PCR, the Luminex-based assay yielded greater than 75% sensitivity and 97% specificity for each virus, and the kappa correlation for detection of all viruses ranged from 0.75 to 1.00. In conclusion, this multiplexed Luminex-based assay provides a potentially rapid, high-throughput, and maneuverable diagnostic tool for major viral pathogens associated with gastroenteritis.
MATERIALS AND METHODS
Sample collection. Two panels of samples were used in this study. The first panel consisted of 10 samples in which RVA, norovirus (NoV) genogroups GI and GII, sapovirus (SaV), HAstV, EAds, HBoV2, enterovirus 71 (EV71), HPeV, and HPBV II were previously identified by PCR with sequencing and/or enzyme-linked immunosorbent assay (ELISA) (5, 9, 21, 25) . This panel was used for initial Luminex assay development and optimization. The second panel of samples consisted of 140 clinical fecal specimens collected from children hospitalized with diarrhea at the First Hospital of Lanzhou University between July 2008 and June 2009. These samples were used to further evaluate the assay.
DNA and RNA extraction. Viral DNA and RNA were extracted from 450 l of 10% fecal suspension in phosphate-buffered saline by using the Viral Nucleic Acid Extraction Kit II (Geneaid Biotech Ltd., Taipei, Taiwan) according to the manufacturer's instructions. The elution volume was 50 l. Extracted DNA or RNA was subdivided into 5-l volumes and stored at Ϫ80°C.
Viral reference preparation. We chose a conservative gene of each virus as a target segment for the viral reference. The PCR fragments from samples positive for RVA (VP6), NoV GI (RNA-dependent RNA polymerase [RDRP] ) and GII (RDRP), SaV (polymerase), HAstV (ORF1a), EAds (hexon), and HBoV2 (NP1) were purified using a QIAquick PCR purification kit (Qiagen) and were identified by sequencing. Then, the cDNA was ligated into a pGEM-T Easy Vector system (Promega) and cloned in DH5␣ Chemically Competent Cell (TransGen Biotech, Beijing). Plasmids of EAds and HBoV2 were purified and sequenced. Plasmids of RVA, NoV GI and GII, SaV, and HAstV were purified, sequenced, linearized with PvuII (New England Biolabs), and purified again. Products were transcribed into RNA with the T7 RiboMAX Express RNAi system or the RiboMAX large scale RNA production systems SP6/T7 kit (Promega Biosciences, Inc.). After DNase I digestion, RNA transcripts were purified with a QIAquick PCR purification kit (Qiagen) and quantified in a spectrophotometer according to the following formulas: number of copies (DNA) ϭ (amount · 6.022 ϫ 10 23 )/(length · 1 ϫ 10 9 · 650), and number of copies (RNA) ϭ (amount · 6.022 ϫ 10 23 )/(length · 1 ϫ 10 9 · 345); then, serial 10-fold dilutions were performed. The in vitro-transcribed RNA and plasmid DNA were then used as quantification standards to determine the sensitivity of the multiplexed Luminex-based assay. Diethylpyrocarbonate (DEPC) water was used as a negative control.
Design of multiplex PCR primers and specific probes. Gene-specific primers and specific capture probes were designed based on sequence information obtained from the National Center for Biotechnology Information (NCBI) (http://www.ncbi.nlm.nih.gov/) and using Lasergene 8.0 (DNASTAR Inc., Madison, WI) and PrimerPlex 2 software (Premier Biosoft, Palo Alto, CA). For target-enriched multiplexing PCR (Tem-PCR), sets of gene-specific primers were selected to amplify 100 to 300 bp targeting conservative gene regions using a melting temperature range of 55 to 60°C, a length range of 18 to 22 bp, and a GC content of 30 to 70%. The primers included tag sequences that can be recognized by universal primers called SuperPrimers (Qiagen, Valencia, CA). The reverse SuperPrimer was labeled with biotin-TEG at its 5= end.
For microsphere-based Luminex detection, specific capture probes were designed to identify 20-nucleotide sequences at a melting temperature range of 55 to 60°C. Each probe was synthesized with 5= Amino Modifier C12 to enable coupling to the carboxyl group located on the microsphere. For all primer and probe sequences, BLAST analysis using the nucleotide database (NCBI) was performed to ensure specificity. All primers and probes were purified by high-pressure liquid chromatography (HPLC) ( Table 1) .
Tem-PCR amplification. After confirming that all of the individual primer pairs allowed for amplification of all seven target viruses in a single PCR, forward and reverse gene-specific primers were mixed together. RNA and DNA were put together for the reaction from the first step of the multiplex PCR. After the Tem PCR amplification conditions were optimized, the multiplex PCR mixtures included 3 l RNA or DNA template mixed with 4 l 5ϫ RT-PCR buffer, 0.8 l enzyme mix (OneStep RT-PCR kit; Qiagen), 400 M deoxynucleoside triphosphates (dNTPs), 1.5 l reverse primer mix (50 to 160 nM), 1.5 l forward primer mix (50 to 160 nM), 0. Hybridization and Luminex analysis. The specific capture probes were bound to different polystyrene microspheres following the Bio-Plex Bead Coupling Protocol (7, 19, 27, 34) . Biotinylated PCR products were hybridized to a fluid microsphere-based array in wells of a 96-well plate and detected using streptavidin-phycoerythrin. To optimize the hybridization conditions, five different hybridization temperatures (46°C, 48°C, 50°C, 52°C, and 55°C) and incubation times (15, 30, 45, 60 , and 90 min) were tested. The optimal hybridization temperature and incubation time proved to be 50°C and 30 min, respectively.
The working microsphere mixture consisted of seven types of beads, each coupled to a unique gene-specific capture probe. A total of 5 l biotin-labeled PCR product was directly mixed with 33 l working microsphere mixture and 12 l Tris-EDTA (TE) buffer (pH 8.0). Hybridization was carried out at 95°C for 3 min followed by 50°C for 30 min. The hybridization product was then transferred to a preheated filter plate and quickly removed by applying a vacuum pressure of 25 to 50 mm Hg. For detection, 100 l streptavidin-R-phycoerythrin (3 g/ml) in 1ϫ tetramethylammonium chloride (TMAC) was added to each well, followed by incubation for 5 min at 50°C. Finally, the signals produced for each bead were analyzed using the Luminex 200 (Luminex Corporation, Austin, TX) and expressed as mean fluorescence intensity (MFI). The cutoff value for a positive result was set at three times the mean MFI value of the negative control.
RESULTS
Specificity of the Luminex-based multiplexed assay. The specificity of our Luminex-based multiplexed assay was examined by testing, in triplicate, 10 different pathogens, including seven target viruses and three other viruses (EV71, HPeV, and HPBV II). TE buffer was used as a blank control, and DEPC water was used as a negative control. As shown in Fig. 1 , the assay was able to detect all target enteric viruses, whereas no signal corresponding to EV71, HPeV, HPBV II, the blank control, or negative control was detected. To further test the performance of this assay, the presence of multiple targets was tested in combination (Fig. 2) . The ability to detect infections with multiple pathogens is important because such infections occur naturally and are often difficult to detect.
Detection sensitivity of the multiplexed Luminex-based assay. The limit of detection for each of the target viruses was determined by testing triplicates of six serial 10-fold dilutions of each reference virus. The limiting dilution was defined as that containing the fewest virus genomic copies that still gave a positive result for all replicates. As shown in Table 2 , the limiting dilution for EAds and HBoV2 was 10 3 copies per reaction and that for RVA, NoV GI and GII, SaV, and HAstV was 10 4 copies per reaction mixture.
Intra-and interassay reproducibilities of the multiplexed Luminex-based assay. To confirm the reproducibility of this method, intra-assay (each sample tested three times within an experiment) and interassay (each sample tested one time in three different experiments) precision was evaluated (28) . For each reference virus, 10 5 -copy dilutions were mixed. These dilutions were used multiple times to confirm the consistency of the viral concentration every time. The coefficient of variation (CV) for each target virus within an experiment ranged from 0.11% to 1.44%, and that between experiments ranged from 1.00% to 4.17% (Table 3).
Evaluation of clinical specimens. To evaluate the assay's performance using clinical specimens, we tested 140 fecal samples using the Luminex-based multiplexed assay and conventional RT-PCR (RT-PCR for RVA, NoV, SaV, and HAstV, and PCR for EAds and HBoV2) in parallel (Table 4) . NoV GI was not detected by either method. Two RVA samples had discrepant results between the Luminex and PCR assays. Four NoV GII samples, one SaV sample, two HAstV samples, and five EAd samples were positive PBV, rotavirus A, NoV GI, NoV GII, SaV, HAstV, EAds, and HBoV2. TE buffer was used as a blank control, and DEPC water was used as a negative control. Biotin-labeled PCR products were separated by probe-coupled beads and are presented in terms of dye signal median fluorescence intensity (MFI) in arbitrary units on the y axis. Each peak was identified by beads coupled with specific capture probes and is indicated on the z axis. The analysis of the mixed-sample detection capacity of the Luminex-based multiplex assay was carried out using four sets of random mixed samples. Mix 1 included HAstV, rotavirus A, and EAds. Mix 2 included NoV GI, NoV GII, and sapovirus. Mix 3 included rotavirus A, NoV GII, and HBoV2. Mix 4 included HAstV, EAds, and HBoV2. DEPC water was used as a negative control. Biotin-labeled PCR products were separated by probe-coupled beads and are presented in terms of dye-signal average median fluorescence intensity (MFI) in arbitrary units on the y axis. Error bars represent 5% of the MFI value.
by PCR but negative by the multiplexed Luminex-based assay. Two HAsV samples and three EAd samples identified as negative by PCR tested positive by the multiplexed Luminex-based array. In addition, five samples identified as coinfections of RVA and HAstV, three of RVA and EAds, three of RVA and NoV GII, and one of RVA, HAstV, and NoV GII were detected by both methods. Based on the 140 clinical samples tested, the sensitivities (true positives) of detection of the different viruses were 100% (RVA), 86.67% (NoV GII), 80% (SaV), 88.24% (HAstV), 76.19% (EAds), and 100% (HBoV2), and the specificities (true negatives) were 97.98%, 100%, 100%, 98.37%, 97.48%, and 100%, respectively. Concordance between the Luminex-based multiplexed assay and conventional PCR results for all viruses was Ͼ90%, and the kappa correlation was Ͼ0.75.
DISCUSSION
Viral gastroenteritis is responsible for a significant proportion of the worldwide diarrheal disease burden. RVA is the principal cause of severe diarrhea, with approximately 95% of children experiencing rotavirus gastroenteritis by 5 years of age (1, 36) . Noroviruses (NoVs) and sapoviruses (SaVs) are members of the family Caliciviridae. NoVs are now recognized as the leading cause of epidemic viral gastroenteritis, and the genogroups GI, GII, and occasionally GIV are associated with human infection (17, 22, 24) . HAstV and EAds are also recognized as important viral agents of diarrhea in infants and the elderly (31) . Although the association between HBoV2 and gastroenteritis is still unknown, the virus has been frequently found in fecal samples from children with gastroenteritis (3, 8, 18) . The accurate diagnosis of enteric viruses is important for clinical care of viral gastroenteritis. Given that many clinical laboratories do not routinely test for the panel of viruses discussed in this article, it is worth a few more sentences to expand on how clinical care will change based on this new information and whether the changes in clinical care will be different in different countries. When dealing with public health crises, accurate diagnoses are important for epidemiologic research as well as clinical care of patients. Previous studies have found at least one viral agent in nearly 43% of clinical diarrheal specimens, with multiple agents detected in 11% (29) . Over the past several years, various detection methods, including cell culture, neutralization tests, antigen detection by immunofluorescence, and PCR, have been widely used for virus identification. Recently, multiplex analysis has become more and more popular. However, multiplexed molecular assays are subject to concerns of decreased sensitivity and specificity related to nonspecific or incompatible amplification, incompatible primer sets, high background, and poor reproducibility (21, 33) . In addition, coinfections are hard to detect, as one virus, usually one at a high titer, often dominates detection assays, especially in cases of single-pass comparative immunological methods. Target-enriched multiplexing PCR (Tem-PCR) addresses these issues by its novel amplification strategy and the application of Luminex xMAP technology (11, 14, 16, 35) . To improve the diagnostic methods for multiplex detection of viral pathogens in diarrhea, we established a novel multiplex PCR technology that allows accurate and rapid detection of multiple pathogens in one sample and therefore provides a molecular differential diagnosis. By using such technology, a public health laboratory can quickly rule out (or rule in) an array of possible pathogens at the initial stage of disease outbreak.
In comparing results of the Luminex-based multiplex assay and conventional PCR, we found that there was no significant difference between the detection rates (measurement agreement was Ͼ90% for all of the tested viruses) in the clinical evaluation. The sensitivity for each virus was Ͼ76%, and the specificity was Ͼ96%. Statistical analysis found that the kappa correlation between the two methods was Ͼ0.75. This indicates that the Luminex-based multiplex assay is almost as specific as the conventional PCR assay. Moreover, it can accurately and rapidly detect multiple pathogens in one sample, which could potentially correlate with clinical significance. Antibiotic abuse is severe in the clinical care of viral gastroenteritis, and the accurate diagnosis of enteric viruses is important for clinical care of gastroenteritis.
Our multiplexed Luminex-based assay has the ability to detect coinfections with a single test and can be performed in less than 6 h, from sample preparation to obtaining the results. Another advantage of this assay is that one tube allows for the identification of seven enteric viruses associated with gastroenteritis. Thus, the potential for cross contamination is, theoretically, much lower, as is the cost of specimen testing, making it more useful in most clinical settings. Our assay exhibited high sensitivity, specificity, and reproducibility with both analytical and clinical specimens. It should be noted that there are not sufficient samples positive for SaV and for HBoV2 to determine meaningful statistics in our study. With the limited specimens available at this time, only preliminary findings were reported in this study. Future priorities should include more specimens to evaluate this novel method.
Our results indicate that our Luminex-based multiplexed assay has potential as a rapid and cost-effective diagnostic tool for viral gastroenteritis. Furthermore, this assay can be expanded to include more specific probes to identify other viral or bacterial agents of gastroenteritis or other diseases.
